Oxford Immunotec Global PLC (NASDAQ:OXFD) CEO Peter Wrighton-Smith sold 55,000 shares of Oxford Immunotec Global PLC stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $16.78, for a total transaction of $922,900.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Peter Wrighton-Smith also recently made the following trade(s):

  • On Thursday, July 6th, Peter Wrighton-Smith sold 27,168 shares of Oxford Immunotec Global PLC stock. The stock was sold at an average price of $15.94, for a total transaction of $433,057.92.

Shares of Oxford Immunotec Global PLC (OXFD) traded up 0.42% during trading on Wednesday, reaching $16.89. 87,622 shares of the company were exchanged. The company’s market capitalization is $389.75 million. Oxford Immunotec Global PLC has a 1-year low of $11.88 and a 1-year high of $19.51. The stock’s 50 day moving average is $15.75 and its 200 day moving average is $15.62.

Oxford Immunotec Global PLC (NASDAQ:OXFD) last released its quarterly earnings data on Tuesday, August 1st. The company reported ($0.32) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.32). Oxford Immunotec Global PLC had a negative net margin of 34.58% and a negative return on equity of 35.76%. The business had revenue of $26.10 million during the quarter, compared to analyst estimates of $25.05 million. During the same quarter last year, the business earned ($0.29) earnings per share. Oxford Immunotec Global PLC’s quarterly revenue was up 35.9% compared to the same quarter last year. Equities analysts anticipate that Oxford Immunotec Global PLC will post ($1.61) earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “Oxford Immunotec Global PLC (OXFD) CEO Sells $922,900.00 in Stock” was originally posted by American Banking News and is owned by of American Banking News. If you are viewing this story on another publication, it was stolen and republished in violation of U.S. & international trademark and copyright law. The correct version of this story can be viewed at https://www.americanbankingnews.com/2017/10/04/oxford-immunotec-global-plc-oxfd-ceo-sells-922900-00-in-stock.html.

A number of hedge funds have recently added to or reduced their stakes in OXFD. Teachers Advisors LLC lifted its position in Oxford Immunotec Global PLC by 19.6% during the fourth quarter. Teachers Advisors LLC now owns 39,932 shares of the company’s stock valued at $597,000 after purchasing an additional 6,550 shares during the last quarter. Nationwide Fund Advisors raised its stake in shares of Oxford Immunotec Global PLC by 1.9% in the first quarter. Nationwide Fund Advisors now owns 13,765 shares of the company’s stock valued at $213,000 after acquiring an additional 254 shares during the period. Russell Investments Group Ltd. purchased a new stake in shares of Oxford Immunotec Global PLC in the first quarter valued at $1,135,000. Wells Fargo & Company MN raised its stake in shares of Oxford Immunotec Global PLC by 129.2% in the first quarter. Wells Fargo & Company MN now owns 65,937 shares of the company’s stock valued at $1,021,000 after acquiring an additional 37,163 shares during the period. Finally, American International Group Inc. raised its stake in shares of Oxford Immunotec Global PLC by 7.1% in the first quarter. American International Group Inc. now owns 13,668 shares of the company’s stock valued at $212,000 after acquiring an additional 904 shares during the period. Institutional investors and hedge funds own 79.21% of the company’s stock.

OXFD has been the topic of a number of analyst reports. Zacks Investment Research cut shares of Oxford Immunotec Global PLC from a “hold” rating to a “sell” rating in a research report on Wednesday, August 30th. Cowen and Company reiterated a “buy” rating and issued a $22.00 target price on shares of Oxford Immunotec Global PLC in a research report on Thursday, August 3rd. BTIG Research initiated coverage on shares of Oxford Immunotec Global PLC in a research report on Thursday, September 28th. They issued a “buy” rating and a $21.00 target price on the stock. Finally, Piper Jaffray Companies reiterated a “buy” rating and issued a $26.00 target price on shares of Oxford Immunotec Global PLC in a research report on Thursday, August 3rd. One analyst has rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $20.75.

About Oxford Immunotec Global PLC

Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company’s product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology.

Insider Buying and Selling by Quarter for Oxford Immunotec Global PLC (NASDAQ:OXFD)

Receive News & Ratings for Oxford Immunotec Global PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global PLC and related companies with MarketBeat.com's FREE daily email newsletter.